RegulatoryCompany release

FDA sets 27 May 2027 decision date for Zenas's obexelimab in IgG4-related disease

🇺🇸 Zenas BioPharma, Inc. (ZBIO) · Thu 05 Nov 2026

The US regulator has accepted Zenas BioPharma's biologics licence application, while the EMA has validated the company's European marketing authorisation application for the same indication.

Zenas BioPharma announced on 5 November 2026 that the US Food and Drug Administration has accepted its biologics licence application (BLA) for obexelimab in IgG4-related disease (IgG4-RD). The agency has set a Prescription Drug User Fee Act (PDUFA) target action date of 27 May 2027.

The European Medicines Agency has also validated the company's marketing authorisation application for obexelimab in the same indication. Validation means the application is complete enough for the formal scientific assessment to begin; it does not indicate any view on the outcome.

According to the company, the submissions rest on results from the Phase 3 INDIGO trial and on bioequivalence data comparing a prefilled pen with a syringe. The device data suggest Zenas is seeking to bring both presentations into the filings.

Alongside the regulatory news, Zenas reported third-quarter 2026 results, citing $647.1 million in cash and investments. It said topline data from the Phase 2 SunStone study in systemic lupus erythematosus (SLE) are expected in the fourth quarter.

What it means for your team

  • Regulatory teams tracking IgG4-RD should note the parallel FDA and EMA reviews, with the US PDUFA goal date fixed at 27 May 2027.
  • The inclusion of prefilled pen versus syringe bioequivalence data signals that device presentation is part of the assessment, relevant to quality and device-combination reviewers.
  • Market-access teams can begin horizon scanning for a possible new biologic option in IgG4-RD, though approval and timing in Europe remain uncertain.
  • SunStone Phase 2 SLE data due in the fourth quarter may indicate the broader development path for obexelimab.

Company's press release (SEC filing): Zenas BioPharma, Inc. ↗

Article written by VigiEye from the official source (Zenas BioPharma, Inc.). Claims are the company's own. AI-assisted; check the source before acting.

More Regulatory All →